The Neuropathology Core of the ADCC functions to provide neuropathologic diagnoses for patients studied by the Clinical Core and to provide brain tissue, CSF, blood serum and DNA for studies by basic scientists. The Neuropathology Core in this application is based at Sun Health Research Institute, where a brain donation program devoted to Alzheimer's disease (AD) research has already been in existence for more than 10 years. Over this time period, more than 600 brains (approximately 50% AD, 25% non-demented controls) have been collected, stored and disbursed to more than 200 AD researchers located all over the world, as well as 4 separate AD laboratories within the Institute, 3 of which have receive NIH funding. Particular strengths of the brain donation program at the Institute include a short postmortem delay (averaging less than 3 hours) and a large number of non-demented control donors. Aside from AD, the full spectrum of dementing disorders is represented, with substantial numbers of cases from even the rarer of these conditions. More than 600 living individuals have consented to brain donation and are being followed with periodic neuropsychological assessments as well as screening tests for extrapyramidal movement disorders. Autopsy cases are fully characterized neuropathologically and are all genotyped for apolipoprotein E alleles. Over the 5 years of the proposed ADCC granting period, approximately 300 cases will come to autopsy; all clinical sites will contribute to this caseload.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-02
Application #
6631205
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2002-08-15
Project End
2003-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sun Health Research Institute
Department
Type
DUNS #
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Subjective Cognitive Impairment and the Broad Autism Phenotype. Alzheimer Dis Assoc Disord 32:284-290
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Salloway, Stephen; Honigberg, Lee A; Cho, William et al. (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther 10:96
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Ortuño-Lizarán, Isabel; Esquiva, Gema; Beach, Thomas G et al. (2018) Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. Acta Neuropathol Commun 6:90
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Chakrabarty, Paramita; Li, Andrew; Ladd, Thomas B et al. (2018) TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. J Exp Med 215:2247-2264

Showing the most recent 10 out of 794 publications